← Back to Search

Cecelia Health plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app for Type 2 Diabetes (ECLIPSE Trial)

N/A
Waitlist Available
Led By Jennifer Lee, PhD
Research Sponsored by LifeScan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up over 1 year
Awards & highlights

ECLIPSE Trial Summary

This trial will test the clinical and economic value of OneTouch Solutions, a selection of devices and health and wellness solutions that people with diabetes can access online. The study will last for one year, and subjects will be monitored for six months to see if there are any improvements in their condition.

Eligible Conditions
  • Type 2 Diabetes

ECLIPSE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~over 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and over 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Changes in A1c from screening to 3 and 6 months in each of the OneTouch Solutions programs
Secondary outcome measures
Change from baseline in diabetes distress as assessed by the diabetes distress scale (DDS) after 3 and 6 months
Change from baseline in medication adherence as assessed by a medication adherence survey after 3 and 6 months
Change from baseline in patient activation measures as assessed by PAM-13 survey after 3 and 6 months
+2 more
Other outcome measures
Change from baseline in A1c as a function of the number of app sessions performed within each of the OneTouch Solutions programs
Changes over time in the number of app sessions performed within each of the OneTouch Solutions programs
Quantify the number of medical insurance claims made by subjects within each of the OneTouch Solutions programs using data harvested from a large medical insurance dataset

ECLIPSE Trial Design

4Treatment groups
Experimental Treatment
Group I: WelldocExperimental Treatment1 Intervention
Multi-condition support program from Welldoc subscription for 1 year. Subjects will also be provided with the OneTouch Verio Reflect glucose meter.
Group II: NoomExperimental Treatment1 Intervention
Noom behavioural weight loss program subscription for 1 year. Subjects will also be provided with the OneTouch Verio Reflect glucose meter and the OneTouch Reveal (OTR) mobile diabetes app.
Group III: FitbitExperimental Treatment1 Intervention
Fitbit Inspire 2 wearable plus 1 year subscription to premium Fitbit application. Subjects will also be provided with the OneTouch Verio Reflect glucose meter and the OneTouch Reveal (OTR) mobile diabetes app.
Group IV: Cecelia HealthExperimental Treatment1 Intervention
Access to live Cecelia health coach on the telephone for 1 year plus access to Cecelia health coach by text messaging (via the OneTouch Reveal mobile diabetes app). Subjects will be provided with the OneTouch Verio Reflect glucose meter and the OneTouch Reveal (OTR) diabetes app.

Find a Location

Who is running the clinical trial?

LifeScanLead Sponsor
33 Previous Clinical Trials
18,859 Total Patients Enrolled
Evidation HealthIndustry Sponsor
19 Previous Clinical Trials
266,482 Total Patients Enrolled
Jennifer Lee, PhDPrincipal InvestigatorEvidation Health

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are we still receiving applications for this experiment?

"According to the latest information available on clinicaltrials.gov, this trial is no longer recruiting patients. Although it was most recently updated on July 19th, 2022, the study is not currently looking for candidates. There are 1456 other trials actively recruiting participants right now."

Answered by AI

Who else is applying?

What state do they live in?
California
How old are they?
18 - 65
What site did they apply to?
Evidation Health
What portion of applicants met pre-screening criteria?
Met criteria
~300 spots leftby Mar 2025